You just read:

Celator® Pharmaceuticals Announces Positive Data for VYXEOS™ in FLT3-ITD Mutated Acute Myeloid Leukemia (AML) Cells Derived from Patients with Newly Diagnosed AML

News provided by

Celator Pharmaceuticals, Inc.

Apr 18, 2016, 08:18 ET